N	B:C1254351
-(	I:C1254351
1H	I:C1254351
-	I:C1254351
Pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
as	O
a	O
novel	O
class	O
of	O
casein	O
kinase	I:C1171766
1δ	I:C1171766
/	O
ε	O
inhibitors	O
:	O
Synthesis	O
,	O
biological	O
evaluation	O
and	O
molecular	O
modeling	I:C0600115
studies	I:C0600115
Described	O
herein	O
is	O
the	O
design	O
,	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
N	O
-	I:C1254351
(	I:C1254351
1H	I:C1254351
-	I:C1254351
pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
against	O
a	O
panel	O
of	O
eight	O
disease	O
relevant	O
protein	O
kinases	I:C0033640
.	O

N	O
-(	I:C1254351
1H	I:C1254351
-	I:C1254351
Pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
as	O
a	O
novel	O
class	O
of	O
casein	B:C1171766
kinase	I:C1171766
1δ	I:C1171766
/	O
ε	O
inhibitors	O
:	O
Synthesis	O
,	O
biological	O
evaluation	O
and	O
molecular	O
modeling	I:C0600115
studies	I:C0600115
Described	O
herein	O
is	O
the	O
design	O
,	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
N	O
-	I:C1254351
(	I:C1254351
1H	I:C1254351
-	I:C1254351
pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
against	O
a	O
panel	O
of	O
eight	O
disease	O
relevant	O
protein	O
kinases	I:C0033640
.	O

N	O
-(	I:C1254351
1H	I:C1254351
-	I:C1254351
Pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
as	O
a	O
novel	O
class	O
of	O
casein	O
kinase	I:C1171766
1δ	I:C1171766
/	O
ε	B:C0752519
inhibitors	O
:	O
Synthesis	O
,	O
biological	O
evaluation	O
and	O
molecular	O
modeling	I:C0600115
studies	I:C0600115
Described	O
herein	O
is	O
the	O
design	O
,	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
N	O
-	I:C1254351
(	I:C1254351
1H	I:C1254351
-	I:C1254351
pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
against	O
a	O
panel	O
of	O
eight	O
disease	O
relevant	O
protein	O
kinases	I:C0033640
.	O

N	O
-(	I:C1254351
1H	I:C1254351
-	I:C1254351
Pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
as	O
a	O
novel	O
class	O
of	O
casein	O
kinase	I:C1171766
1δ	I:C1171766
/	O
ε	O
inhibitors	B:C0243077
:	O
Synthesis	O
,	O
biological	O
evaluation	O
and	O
molecular	O
modeling	I:C0600115
studies	I:C0600115
Described	O
herein	O
is	O
the	O
design	O
,	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
N	O
-	I:C1254351
(	I:C1254351
1H	I:C1254351
-	I:C1254351
pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
against	O
a	O
panel	O
of	O
eight	O
disease	O
relevant	O
protein	O
kinases	I:C0033640
.	O

N	O
-(	I:C1254351
1H	I:C1254351
-	I:C1254351
Pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
as	O
a	O
novel	O
class	O
of	O
casein	O
kinase	I:C1171766
1δ	I:C1171766
/	O
ε	O
inhibitors	O
:	O
Synthesis	O
,	O
biological	O
evaluation	O
and	O
molecular	B:C0600115
modeling	I:C0600115
studies	I:C0600115
Described	O
herein	O
is	O
the	O
design	O
,	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
N	O
-	I:C1254351
(	I:C1254351
1H	I:C1254351
-	I:C1254351
pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
against	O
a	O
panel	O
of	O
eight	O
disease	O
relevant	O
protein	O
kinases	I:C0033640
.	O

N	O
-(	I:C1254351
1H	I:C1254351
-	I:C1254351
Pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
as	O
a	O
novel	O
class	O
of	O
casein	O
kinase	I:C1171766
1δ	I:C1171766
/	O
ε	O
inhibitors	O
:	O
Synthesis	O
,	O
biological	O
evaluation	O
and	O
molecular	O
modeling	I:C0600115
studies	I:C0600115
Described	O
herein	O
is	O
the	O
design	O
,	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
N	B:C1254351
-	I:C1254351
(	I:C1254351
1H	I:C1254351
-	I:C1254351
pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
against	O
a	O
panel	O
of	O
eight	O
disease	O
relevant	O
protein	O
kinases	I:C0033640
.	O

N	O
-(	I:C1254351
1H	I:C1254351
-	I:C1254351
Pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
as	O
a	O
novel	O
class	O
of	O
casein	O
kinase	I:C1171766
1δ	I:C1171766
/	O
ε	O
inhibitors	O
:	O
Synthesis	O
,	O
biological	O
evaluation	O
and	O
molecular	O
modeling	I:C0600115
studies	I:C0600115
Described	O
herein	O
is	O
the	O
design	O
,	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
N	O
-	I:C1254351
(	I:C1254351
1H	I:C1254351
-	I:C1254351
pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
against	O
a	O
panel	O
of	O
eight	O
disease	B:C0012634
relevant	O
protein	O
kinases	I:C0033640
.	O

N	O
-(	I:C1254351
1H	I:C1254351
-	I:C1254351
Pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
as	O
a	O
novel	O
class	O
of	O
casein	O
kinase	I:C1171766
1δ	I:C1171766
/	O
ε	O
inhibitors	O
:	O
Synthesis	O
,	O
biological	O
evaluation	O
and	O
molecular	O
modeling	I:C0600115
studies	I:C0600115
Described	O
herein	O
is	O
the	O
design	O
,	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
a	O
series	O
of	O
N	O
-	I:C1254351
(	I:C1254351
1H	I:C1254351
-	I:C1254351
pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
against	O
a	O
panel	O
of	O
eight	O
disease	O
relevant	O
protein	B:C0033640
kinases	I:C0033640
.	O

The	O
kinase	B:C2247121
inhibition	I:C2247121
results	O
indicated	O
that	O
two	O
compounds	O
inhibited	O
casein	O
kinase	I:C1171766
1δ	I:C1171766
/	O
ε	O
(	O
CK1	O
δ	I:C1171766
/	O
ε	O
)	O
with	O
some	O
selectivity	O
over	O
related	O
kinases	O
,	O
namely	O
CDK5	O
/	I:C0249586
p25	I:C0249586
,	O
GSK	O
-	I:C3853562
3α	I:C3853562
/	O
β	O
,	O
and	O
DYRK1A	O
.	O

The	O
kinase	O
inhibition	I:C2247121
results	O
indicated	B:C1444656
that	O
two	O
compounds	O
inhibited	O
casein	O
kinase	I:C1171766
1δ	I:C1171766
/	O
ε	O
(	O
CK1	O
δ	I:C1171766
/	O
ε	O
)	O
with	O
some	O
selectivity	O
over	O
related	O
kinases	O
,	O
namely	O
CDK5	O
/	I:C0249586
p25	I:C0249586
,	O
GSK	O
-	I:C3853562
3α	I:C3853562
/	O
β	O
,	O
and	O
DYRK1A	O
.	O

The	O
kinase	O
inhibition	I:C2247121
results	O
indicated	O
that	O
two	O
compounds	B:C1254351
inhibited	O
casein	O
kinase	I:C1171766
1δ	I:C1171766
/	O
ε	O
(	O
CK1	O
δ	I:C1171766
/	O
ε	O
)	O
with	O
some	O
selectivity	O
over	O
related	O
kinases	O
,	O
namely	O
CDK5	O
/	I:C0249586
p25	I:C0249586
,	O
GSK	O
-	I:C3853562
3α	I:C3853562
/	O
β	O
,	O
and	O
DYRK1A	O
.	O

The	O
kinase	O
inhibition	I:C2247121
results	O
indicated	O
that	O
two	O
compounds	O
inhibited	O
casein	B:C1171766
kinase	I:C1171766
1δ	I:C1171766
/	O
ε	O
(	O
CK1	O
δ	I:C1171766
/	O
ε	O
)	O
with	O
some	O
selectivity	O
over	O
related	O
kinases	O
,	O
namely	O
CDK5	O
/	I:C0249586
p25	I:C0249586
,	O
GSK	O
-	I:C3853562
3α	I:C3853562
/	O
β	O
,	O
and	O
DYRK1A	O
.	O

The	O
kinase	O
inhibition	I:C2247121
results	O
indicated	O
that	O
two	O
compounds	O
inhibited	O
casein	O
kinase	I:C1171766
1δ	I:C1171766
/	O
ε	B:C0752519
(	O
CK1	O
δ	I:C1171766
/	O
ε	O
)	O
with	O
some	O
selectivity	O
over	O
related	O
kinases	O
,	O
namely	O
CDK5	O
/	I:C0249586
p25	I:C0249586
,	O
GSK	O
-	I:C3853562
3α	I:C3853562
/	O
β	O
,	O
and	O
DYRK1A	O
.	O

The	O
kinase	O
inhibition	I:C2247121
results	O
indicated	O
that	O
two	O
compounds	O
inhibited	O
casein	O
kinase	I:C1171766
1δ	I:C1171766
/	O
ε	O
(	O
CK1	B:C1171766
δ	I:C1171766
/	O
ε	O
)	O
with	O
some	O
selectivity	O
over	O
related	O
kinases	O
,	O
namely	O
CDK5	O
/	I:C0249586
p25	I:C0249586
,	O
GSK	O
-	I:C3853562
3α	I:C3853562
/	O
β	O
,	O
and	O
DYRK1A	O
.	O

The	O
kinase	O
inhibition	I:C2247121
results	O
indicated	O
that	O
two	O
compounds	O
inhibited	O
casein	O
kinase	I:C1171766
1δ	I:C1171766
/	O
ε	O
(	O
CK1	O
δ	I:C1171766
/	O
ε	B:C0752519
)	O
with	O
some	O
selectivity	O
over	O
related	O
kinases	O
,	O
namely	O
CDK5	O
/	I:C0249586
p25	I:C0249586
,	O
GSK	O
-	I:C3853562
3α	I:C3853562
/	O
β	O
,	O
and	O
DYRK1A	O
.	O

The	O
kinase	O
inhibition	I:C2247121
results	O
indicated	O
that	O
two	O
compounds	O
inhibited	O
casein	O
kinase	I:C1171766
1δ	I:C1171766
/	O
ε	O
(	O
CK1	O
δ	I:C1171766
/	O
ε	O
)	O
with	O
some	O
selectivity	O
over	O
related	O
kinases	B:C0033640
,	O
namely	O
CDK5	O
/	I:C0249586
p25	I:C0249586
,	O
GSK	O
-	I:C3853562
3α	I:C3853562
/	O
β	O
,	O
and	O
DYRK1A	O
.	O

The	O
kinase	O
inhibition	I:C2247121
results	O
indicated	O
that	O
two	O
compounds	O
inhibited	O
casein	O
kinase	I:C1171766
1δ	I:C1171766
/	O
ε	O
(	O
CK1	O
δ	I:C1171766
/	O
ε	O
)	O
with	O
some	O
selectivity	O
over	O
related	O
kinases	O
,	O
namely	O
CDK5	B:C0249586
/	I:C0249586
p25	I:C0249586
,	O
GSK	O
-	I:C3853562
3α	I:C3853562
/	O
β	O
,	O
and	O
DYRK1A	O
.	O

The	O
kinase	O
inhibition	I:C2247121
results	O
indicated	O
that	O
two	O
compounds	O
inhibited	O
casein	O
kinase	I:C1171766
1δ	I:C1171766
/	O
ε	O
(	O
CK1	O
δ	I:C1171766
/	O
ε	O
)	O
with	O
some	O
selectivity	O
over	O
related	O
kinases	O
,	O
namely	O
CDK5	O
/	I:C0249586
p25	I:C0249586
,	O
GSK	B:C3853562
-	I:C3853562
3α	I:C3853562
/	O
β	O
,	O
and	O
DYRK1A	O
.	O

The	O
kinase	O
inhibition	I:C2247121
results	O
indicated	O
that	O
two	O
compounds	O
inhibited	O
casein	O
kinase	I:C1171766
1δ	I:C1171766
/	O
ε	O
(	O
CK1	O
δ	I:C1171766
/	O
ε	O
)	O
with	O
some	O
selectivity	O
over	O
related	O
kinases	O
,	O
namely	O
CDK5	O
/	I:C0249586
p25	I:C0249586
,	O
GSK	O
-	I:C3853562
3α	I:C3853562
/	O
β	B:C4283740
,	O
and	O
DYRK1A	O
.	O

The	O
kinase	O
inhibition	I:C2247121
results	O
indicated	O
that	O
two	O
compounds	O
inhibited	O
casein	O
kinase	I:C1171766
1δ	I:C1171766
/	O
ε	O
(	O
CK1	O
δ	I:C1171766
/	O
ε	O
)	O
with	O
some	O
selectivity	O
over	O
related	O
kinases	O
,	O
namely	O
CDK5	O
/	I:C0249586
p25	I:C0249586
,	O
GSK	O
-	I:C3853562
3α	I:C3853562
/	O
β	O
,	O
and	O
DYRK1A	B:C1453762
.	O

Docking	B:C1522290
studies	O
with	O
3c	O
and	O
3d	O
revealed	O
the	O
key	O
interactions	O
with	O
desired	O
amino	O
acids	I:C0002520
in	O
the	O
ATP	O
binding	O
site	I:C1149343
of	O
CK1	O
δ	I:C1171766
.	O

Docking	O
studies	B:C0947630
with	O
3c	O
and	O
3d	O
revealed	O
the	O
key	O
interactions	O
with	O
desired	O
amino	O
acids	I:C0002520
in	O
the	O
ATP	O
binding	O
site	I:C1149343
of	O
CK1	O
δ	I:C1171766
.	O

Docking	O
studies	O
with	O
3c	B:C1254351
and	O
3d	O
revealed	O
the	O
key	O
interactions	O
with	O
desired	O
amino	O
acids	I:C0002520
in	O
the	O
ATP	O
binding	O
site	I:C1149343
of	O
CK1	O
δ	I:C1171766
.	O

Docking	O
studies	O
with	O
3c	O
and	O
3d	B:C1254351
revealed	O
the	O
key	O
interactions	O
with	O
desired	O
amino	O
acids	I:C0002520
in	O
the	O
ATP	O
binding	O
site	I:C1149343
of	O
CK1	O
δ	I:C1171766
.	O

Docking	O
studies	O
with	O
3c	O
and	O
3d	O
revealed	O
the	O
key	O
interactions	O
with	O
desired	O
amino	B:C0002520
acids	I:C0002520
in	O
the	O
ATP	O
binding	O
site	I:C1149343
of	O
CK1	O
δ	I:C1171766
.	O

Docking	O
studies	O
with	O
3c	O
and	O
3d	O
revealed	O
the	O
key	O
interactions	O
with	O
desired	O
amino	O
acids	I:C0002520
in	O
the	O
ATP	B:C0001480
binding	O
site	I:C1149343
of	O
CK1	O
δ	I:C1171766
.	O

Docking	O
studies	O
with	O
3c	O
and	O
3d	O
revealed	O
the	O
key	O
interactions	O
with	O
desired	O
amino	O
acids	I:C0002520
in	O
the	O
ATP	O
binding	B:C1149343
site	I:C1149343
of	O
CK1	O
δ	I:C1171766
.	O

Docking	O
studies	O
with	O
3c	O
and	O
3d	O
revealed	O
the	O
key	O
interactions	O
with	O
desired	O
amino	O
acids	I:C0002520
in	O
the	O
ATP	O
binding	O
site	I:C1149343
of	O
CK1	B:C1171766
δ	I:C1171766
.	O

Furthermore	O
,	O
compound	B:C1254351
3	I:C1254351
c	I:C1254351
also	O
elicited	O
selective	O
cytotoxic	O
activity	O
against	O
the	O
pancreas	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
(	O
PANC	O
-	I:C1335302
1	I:C1335302
)	O
cell	O
line	I:C0085983
.	O

Furthermore	O
,	O
compound	O
3	I:C1254351
c	I:C1254351
also	O
elicited	O
selective	O
cytotoxic	O
activity	O
against	O
the	O
pancreas	B:C1335302
ductal	I:C1335302
adenocarcinoma	I:C1335302
(	O
PANC	O
-	I:C1335302
1	I:C1335302
)	O
cell	O
line	I:C0085983
.	O

Furthermore	O
,	O
compound	O
3	I:C1254351
c	I:C1254351
also	O
elicited	O
selective	O
cytotoxic	O
activity	O
against	O
the	O
pancreas	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
(	O
PANC	B:C1335302
-	I:C1335302
1	I:C1335302
)	O
cell	O
line	I:C0085983
.	O

Furthermore	O
,	O
compound	O
3	I:C1254351
c	I:C1254351
also	O
elicited	O
selective	O
cytotoxic	O
activity	O
against	O
the	O
pancreas	O
ductal	I:C1335302
adenocarcinoma	I:C1335302
(	O
PANC	O
-	I:C1335302
1	I:C1335302
)	O
cell	B:C0085983
line	I:C0085983
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
this	O
study	B:C2603343
establish	O
N	O
-	I:C1254351
(	I:C1254351
1H	I:C1254351
-	I:C1254351
pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
especially	O
3c	O
and	O
3d	O
as	O
valuable	O
lead	O
molecules	O
with	O
great	O
potential	O
for	O
CK1	O
δ	I:C1171766
/	O
ε	O
inhibitor	O
development	O
targeting	O
neurodegenerative	O
disorders	I:C0524851
and	O
cancer	O
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
this	O
study	O
establish	O
N	B:C1254351
-	I:C1254351
(	I:C1254351
1H	I:C1254351
-	I:C1254351
pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
especially	O
3c	O
and	O
3d	O
as	O
valuable	O
lead	O
molecules	O
with	O
great	O
potential	O
for	O
CK1	O
δ	I:C1171766
/	O
ε	O
inhibitor	O
development	O
targeting	O
neurodegenerative	O
disorders	I:C0524851
and	O
cancer	O
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
this	O
study	O
establish	O
N	O
-	I:C1254351
(	I:C1254351
1H	I:C1254351
-	I:C1254351
pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
especially	O
3c	B:C1254351
and	O
3d	O
as	O
valuable	O
lead	O
molecules	O
with	O
great	O
potential	O
for	O
CK1	O
δ	I:C1171766
/	O
ε	O
inhibitor	O
development	O
targeting	O
neurodegenerative	O
disorders	I:C0524851
and	O
cancer	O
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
this	O
study	O
establish	O
N	O
-	I:C1254351
(	I:C1254351
1H	I:C1254351
-	I:C1254351
pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
especially	O
3c	O
and	O
3d	B:C1254351
as	O
valuable	O
lead	O
molecules	O
with	O
great	O
potential	O
for	O
CK1	O
δ	I:C1171766
/	O
ε	O
inhibitor	O
development	O
targeting	O
neurodegenerative	O
disorders	I:C0524851
and	O
cancer	O
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
this	O
study	O
establish	O
N	O
-	I:C1254351
(	I:C1254351
1H	I:C1254351
-	I:C1254351
pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
especially	O
3c	O
and	O
3d	O
as	O
valuable	O
lead	O
molecules	O
with	O
great	O
potential	O
for	O
CK1	B:C1171766
δ	I:C1171766
/	O
ε	O
inhibitor	O
development	O
targeting	O
neurodegenerative	O
disorders	I:C0524851
and	O
cancer	O
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
this	O
study	O
establish	O
N	O
-	I:C1254351
(	I:C1254351
1H	I:C1254351
-	I:C1254351
pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
especially	O
3c	O
and	O
3d	O
as	O
valuable	O
lead	O
molecules	O
with	O
great	O
potential	O
for	O
CK1	O
δ	I:C1171766
/	O
ε	B:C0752519
inhibitor	O
development	O
targeting	O
neurodegenerative	O
disorders	I:C0524851
and	O
cancer	O
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
this	O
study	O
establish	O
N	O
-	I:C1254351
(	I:C1254351
1H	I:C1254351
-	I:C1254351
pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
especially	O
3c	O
and	O
3d	O
as	O
valuable	O
lead	O
molecules	O
with	O
great	O
potential	O
for	O
CK1	O
δ	I:C1171766
/	O
ε	O
inhibitor	B:C0243077
development	O
targeting	O
neurodegenerative	O
disorders	I:C0524851
and	O
cancer	O
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
this	O
study	O
establish	O
N	O
-	I:C1254351
(	I:C1254351
1H	I:C1254351
-	I:C1254351
pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
especially	O
3c	O
and	O
3d	O
as	O
valuable	O
lead	O
molecules	O
with	O
great	O
potential	O
for	O
CK1	O
δ	I:C1171766
/	O
ε	O
inhibitor	O
development	O
targeting	O
neurodegenerative	B:C0524851
disorders	I:C0524851
and	O
cancer	O
.	O

Taken	O
together	O
,	O
the	O
results	O
of	O
this	O
study	O
establish	O
N	O
-	I:C1254351
(	I:C1254351
1H	I:C1254351
-	I:C1254351
pyrazol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
yl	I:C1254351
)	I:C1254351
quinazolin	I:C1254351
-	I:C1254351
4	I:C1254351
-	I:C1254351
amines	I:C1254351
especially	O
3c	O
and	O
3d	O
as	O
valuable	O
lead	O
molecules	O
with	O
great	O
potential	O
for	O
CK1	O
δ	I:C1171766
/	O
ε	O
inhibitor	O
development	O
targeting	O
neurodegenerative	O
disorders	I:C0524851
and	O
cancer	B:C0006826
.	O

